jcxh-211
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2022 (NCT05539157)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06781125 | Phase 1 | Feb 10, 2025 | Immorna Biotherapeutics, Inc., Sun Yat-Sen University |
| NCT06468605 | Phase 1 | Oct 1, 2024 | Duke University |
| NCT05727839 | Phase 1 | Feb 24, 2023 | Immorna Biotherapeutics, Inc., Sun Yat-Sen University |
| NCT05539157 | Phase 1 | Oct 18, 2022 | Immorna Biotherapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immorna Biotherapeutics, Inc. | For profit | 3 | 3 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1